LIME bridged effector and tumor cells, induced transcriptional programs of T cell activation, metabolism and proliferation, and enhanced cytotoxicity across cancer cell lines and patient-derived organoids, establishing LIME as a versatile living therapeutic platform for programmable, tumor-restricted immune orchestration.
Chimeric antigen receptor (CAR)-based cell therapies have transformed the treatment of selected hematologic malignancies, yet their efficacy in solid tumors remains limited due to antigen heterogeneity, inadequate trafficking, physical and metabolic barriers, immune suppression, and poor persistence of transferred cell...
BACKGROUND
Mucosal-associated invariant T (MAIT) cells are innate-like T lymphocytes that recognize riboflavin-derived metabolites presented by the monomorphic major histocompatibility complex (MHC)-class I-related molecule MR1. MAIT cells are highly enriched in the human liver and are increasingly implicated in liver...
Yan-Ruide Li, Xin-Yuan Shen, Yi-Chen Zhu et al.· i Medicina· 1 citation
The approach integrates enzyme/prodrug therapy and immunotherapy into a single bacterial delivery system, overcoming key limitations of conventional therapies by providing a rationally designed framework for spatially controlled chemoimmunotherapy.
This review outlines the evolution of effector-cell-engaging bsAb formats, such as BiTEs, DARTs, TandAbs and IgG-like constructs, along with engineering strategies to enhance Fc function, valency, half-life, safety and efficacy.
A. Gholap, P. Khuspe, Darshana Morankar et al.· Drug Discovery Today· 0 citations
Oncolytic virotherapy (OVT) has emerged as a promising immunotherapeutic strategy that combines selective tumor destruction with systemic immune activation. However, durable clinical responses remain limited because current approaches largely focus on viral replication and oncolysis while overlooking the immune network...
Chuan-Jian Wu, Wang-Lu Gu, An-Dong Qin et al.· Critical reviews in oncology...· 0 citations